There has been much contention regarding how the deadly COVID-19 pandemic originated. The first reported case of the disease was in Wuhan (Hubei province, China). The virus – SARS-CoV-2 – is believed to have been passed from animals to humans, but new data reveals pangolins could be linked to COVID-19 transmission.
Moderna has announced that the first participants have been dosed in a Phase I study of their mRNA candidate vaccine against SARS-CoV-2, the virus that causes COVID-19.
The first clinical trial assessing two triple artemisinin-based combination therapies (TACTs) for treating malaria has suggested these are effective and present no safety concerns.
Long-term follow-up of the ‘London patient’, the second patient to ever achieve sustained HIV remission after ceasing antiretroviral treatment, has suggested that there is no active detectable HIV virus remaining.
Upon investigating links between the risk of malaria in developing countries and the products demanded by consumers worldwide, researchers have estimated that a significant fraction of the malaria risk in deforestation hotspots is driven by the international trade of products.
Novel research suggests that some drugs may prevent the acquisition of resistance genes by preventing the induction of bacterial ‘competence’.
Catch up on February’s industry headlines, including an MRSA breakthrough, a patent lawsuit, and the latest updates on the coronavirus outbreak and its impact on the biotechnology industry worldwide.
The development of a paper-based, point-of-care diagnostic test may enable clinicians to rapidly detect bacterial infections and their antibiotic susceptibility with a simple colorimetric readout.